Eton Pharmaceuticals, Inc.
ETON · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.79 | -0.58 | -0.36 | 0.75 |
| FCF Yield | 2.01% | 2.08% | 0.60% | -2.56% |
| EV / EBITDA | -403.90 | -1,229.48 | -769.45 | 308.51 |
| Quality | ||||
| ROIC | -2.13% | -2.30% | -0.84% | 1.31% |
| Gross Margin | 34.97% | 63.00% | 57.06% | 55.60% |
| Cash Conversion Ratio | -6.24 | -3.08 | -1.33 | 1.28 |
| Growth | ||||
| Revenue 3-Year CAGR | 28.91% | 26.10% | 25.62% | 22.44% |
| Free Cash Flow Growth | 47.53% | 280.81% | 123.49% | -284.59% |
| Safety | ||||
| Net Debt / EBITDA | 24.85 | -16.74 | -26.93 | 12.73 |
| Interest Coverage | 2.30 | -1.23 | -0.40 | 0.47 |
| Efficiency | ||||
| Inventory Turnover | 0.87 | 0.29 | 0.54 | 0.34 |
| Cash Conversion Cycle | 68.42 | 218.41 | 191.51 | 234.01 |